blindness

7-methylxanthine is being reformulated into a sustained-release oral therapy aimed at improving long-term control of axial elongation in childhood myopia.

Emerging optogenetic, gene, and cell therapies are moving beyond single-gene treatments, offering hope for a broader range of patients with retinitis pigmentosa.

These latest deals give Lilly a complementary portfolio of life-changing therapies and scalable gene therapy platforms.

Via a unique regulatory route in the UK, scientists found that a gene therapy restored vision in young kids with a very rare and severe retinal dystrophy.

Plummeting blood sugar can accelerate eye damage due to diabetes. Results in mice suggest that a new drug targeting hypoxia inducible factor could help.

Researchers use retinal organoids to screen drugs and hope to transplant them into the eyes of people with blindness in the coming years.

In diabetic macular edema, senescent cells build up in the retina, leading to vision loss. A new drug forces these undead cells to die, healing the retina.

Eye injections are the only way to treat diabetic retinopathy, but many refuse to get them. Now, eye drops and pills are on their way.

Neuroscientists safely delivered a critical gene that improved vision for two patients with Leber congenital amaurosis.

Researchers are developing gene and cell therapies and prosthetics to help patients with blindness regain some vision. The first major prosthetic, the Argus II, was just discontinued. Where will the field go from here?